Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 7/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TPMT | P51580 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4037522 | 0.80 | HTT (0.38) | TSHRTPMTLMNAMAPK1 | |
| SCHEMBL4038616 | 0.78 | XDH (0.38) | — | |
| SCHEMBL4046605 | 0.75 | MET (0.37) | HCAR3TSHRTPMTMETPOLB | |
| SCHEMBL28411101 | 0.75 | HCAR3 (0.40) | HCAR3TSHRTPMTCASP6MET | |
| SCHEMBL4037640 | 0.74 | KDM4E (0.32) | — | |
| SCHEMBL30792849 | 0.71 | HCAR3 (0.58) | HCAR3TSHRCASP6LMNAAPEX1 | |
| SCHEMBL27191011 | 0.71 | HCAR3 (0.58) | HCAR3TSHRCASP6LMNAAPEX1 | |
| SCHEMBL26310184 | 0.70 | AAK1 (0.37) | METLMNAMAPT | |
| SCHEMBL14060781 | 0.69 | TPMT (0.54) | HCAR3TSHRTPMTCASP6LMNA | |
| SCHEMBL18785419 | 0.67 | TSHR (0.45) | HCAR3TSHRTPMTCASP6MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268443-B1 | 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-6972297-B2 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-12-06 | — | — | US | disclosed |
| US-20030114674-A1 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-19 | — | — | US | disclosed |
| EP-1268443-A1 | 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE | SmithKline Beecham p.l.c. (GB) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074788-A1 | 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114674-A1 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | MSH6, MSH2, PMS2 | HCAR3 940/4885TSHR 3000/4885TPMT 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.